Better margins and new drugs keep GlaxoSmithKline on track

LONDON, April 27 (Reuters) - Improving margins in consumer health and growing demand for new drugs helped lift GlaxoSmithKline's underlying earnings a better-than-expected 14 percent in the first quarter, keeping it on course to achieve a promised return to growth in 2016.